Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)

Revista de Investigacion Clinica

Volumn 56, Issue 2, 2004, Pages 126-129

  Barre Sinoussi F ^a   Chermann, J C ^a   Rey, F ^a   Nugeyre, M T ^a   Chamaret, S ^a   Gruest, J ^a   Dauguet, C ^a   Axler Blin, C ^a   Vezinet Brun F ^b   Rouzioux, C ^b   Rozenbaum, W ^c   Montagnier, L ^a  

^a INSTITUT PASTEUR   (France)

^b BICHAT HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; MAGNESIUM; RNA DIRECTED DNA POLYMERASE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CAUCASIAN; CELL BUDDING; CELL MEMBRANE; ENZYME ACTIVITY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION RISK; LYMPHOCYTE; MALE; NONHUMAN; PRECIPITATION; RETROVIRUS; RNA VIRUS; SYMPTOMATOLOGY; UMBILICAL CORD BLOOD; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HISTORY, 20TH CENTURY; HUMANS; RETROVIRIDAE; RISK FACTORS;

EID: 4243098427     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Centers for Disease Control, Task Force on Kaposi's Sarcoma and Opportunistic Infections, N. Engl. J. Med. 306, 248 (1982).
2. M. Marmor et al., Lancet 1982-II, 1083 (1982);
3. S. Fannin et al., Morbid. Mortal. Weekly Rep. 31, 305 (1982).
4. Centers for Disease Control, Task Force on Kaposi's Sarcoma and Opportunistic Infections, Morbid. Mortal. Weekly Rep. 31, 507 (1982).
5. M. C. Poon et al., ibid., p. 644.
6. R. E. Stahl, A. Friedman-Kien, R. Dubin, M. Marmor, S. Zolla Parner, Am. J. Med. 73, 171 (1982).
7. D. Mildvan et al., Morbid. Mortal. Weekly Rep. 31, 249 (1982).
8. R. O'Reilly et al., ibid., p. 665.
9. W. Rozenbaum, et al., Lancet 1982-II, 572 (1982).
10. R. C. Gallo and M. S. Reitz, Jr., J. Natl. Cancer Inst. 69 (No. 6). 1209 (1982).
11. V. S. Kalyanaraman et al., Science 218, 571 (1982).
12. E. Gelmann, F. Wong-Staal, R. Gallo, personal communication.
13. -5), and 5 percent TCGF, free of PHA.
14. F. Barré-Sinoussi et al., Ann. Microbiol. (Inst. Pasteur) 130B, 349 (1979).
15. B. J. Poiesz et al., Proc. Natl. Acad. Sci. U.S.A. 77, 7415 (1980).
16. M Robert-Guroff et al., J. Exp. Med. 154, 1957 (1981).
17. V. S. Kalyanaraman et al., J. Virol, 38, 906 (1981).
18. M. Popovic, P. S. Sarin, M. Robert-Guroff, V. S. Kalyanaraman, D. Mann, J. Minowada, R. C. Gallo, Science 219, 856 (1983).
19. R. E. Karess, et al., Proc. Natl. Acad. Sci. U.S.A. 76, 3154 (1979).
20. U. K. Laemmli, Nature (London) 227, 608 (1970).
21. We thank Dr. Fradellizi for gifts of T-cell growth factor, R. C. Gallo for providing antibodies to HTLV and for HTLV-producing cells, Mrs. Le François for preparation of the cord lymphocytes, M. Lavergne (Institut Pasteur, Production) for gifts of fluorescein-conjugated antisera, F. Huraud for performing some of the HTLV tests, and members of the French Working Group on AIDS for helpful discussion.